Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$39.85M$39.85Mderivedno prior Q4 2021 on file Net Income$33.94M$33.94MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$34,210,000N/M Operating Cash Flowderived$28,791,000N/M Margins · derivedOperating margin85.8%
Net margin85.2%
ended Dec 31, 2022 · filed Mar 30, 2023 · 89 d after period end